Preferential recruitment of Th17 cells to cervical cancer via CCR6-CCL20 pathway.

Our previous studies suggest that Th17 cells accumulate within tumor tissues and correlate with recurrence of cervical cancer patients. However, the source of the increased tumor-infiltrating Th17 cells remains poorly understood. We investigated the prevalence, phenotype and trafficking property of...

Full description

Bibliographic Details
Main Authors: Qing Yu, Xiang-ming Lou, Yan He
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4359139?pdf=render
id doaj-626dbc60664641dd916ce96a89440b07
record_format Article
spelling doaj-626dbc60664641dd916ce96a89440b072020-11-25T00:50:46ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01103e012085510.1371/journal.pone.0120855Preferential recruitment of Th17 cells to cervical cancer via CCR6-CCL20 pathway.Qing YuXiang-ming LouYan HeOur previous studies suggest that Th17 cells accumulate within tumor tissues and correlate with recurrence of cervical cancer patients. However, the source of the increased tumor-infiltrating Th17 cells remains poorly understood. We investigated the prevalence, phenotype and trafficking property of Th17 cells in patients with cervical cancer. Our results showed that Th17 cells highly aggregated within tumor tissues in an activated phenotype with markedly increased expression of CCR6. Correspondingly, level of CCL20 in the tumor tissues was significantly higher than that in non-tumor and normal control tissues, and strongly positively associated with Th17 cells. Further, in vitro migration assay showed CCL20 had effective chemotaxis to circulating Th17 cells. In conclusion, Th17 cells are recruited into tumor tissues preferentially through CCR6-CCL20 pathway, which can serve as a novel therapeutic target for cervical cancer.http://europepmc.org/articles/PMC4359139?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Qing Yu
Xiang-ming Lou
Yan He
spellingShingle Qing Yu
Xiang-ming Lou
Yan He
Preferential recruitment of Th17 cells to cervical cancer via CCR6-CCL20 pathway.
PLoS ONE
author_facet Qing Yu
Xiang-ming Lou
Yan He
author_sort Qing Yu
title Preferential recruitment of Th17 cells to cervical cancer via CCR6-CCL20 pathway.
title_short Preferential recruitment of Th17 cells to cervical cancer via CCR6-CCL20 pathway.
title_full Preferential recruitment of Th17 cells to cervical cancer via CCR6-CCL20 pathway.
title_fullStr Preferential recruitment of Th17 cells to cervical cancer via CCR6-CCL20 pathway.
title_full_unstemmed Preferential recruitment of Th17 cells to cervical cancer via CCR6-CCL20 pathway.
title_sort preferential recruitment of th17 cells to cervical cancer via ccr6-ccl20 pathway.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description Our previous studies suggest that Th17 cells accumulate within tumor tissues and correlate with recurrence of cervical cancer patients. However, the source of the increased tumor-infiltrating Th17 cells remains poorly understood. We investigated the prevalence, phenotype and trafficking property of Th17 cells in patients with cervical cancer. Our results showed that Th17 cells highly aggregated within tumor tissues in an activated phenotype with markedly increased expression of CCR6. Correspondingly, level of CCL20 in the tumor tissues was significantly higher than that in non-tumor and normal control tissues, and strongly positively associated with Th17 cells. Further, in vitro migration assay showed CCL20 had effective chemotaxis to circulating Th17 cells. In conclusion, Th17 cells are recruited into tumor tissues preferentially through CCR6-CCL20 pathway, which can serve as a novel therapeutic target for cervical cancer.
url http://europepmc.org/articles/PMC4359139?pdf=render
work_keys_str_mv AT qingyu preferentialrecruitmentofth17cellstocervicalcancerviaccr6ccl20pathway
AT xiangminglou preferentialrecruitmentofth17cellstocervicalcancerviaccr6ccl20pathway
AT yanhe preferentialrecruitmentofth17cellstocervicalcancerviaccr6ccl20pathway
_version_ 1725246653906026496